Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177140 | 0.97 | SMN1; SMN2 (0.33) | SMN1; SMN2ESR2 | |
| SCHEMBL486771 | 0.94 | ESR2 (0.32) | SMN1; SMN2ESR2 | |
| SCHEMBL428515 | 0.88 | — | — | |
| SCHEMBL287483 | 0.88 | ESR2 (0.34) | ESR2 | |
| SCHEMBL428337 | 0.85 | ESR2 (0.38) | SMN1; SMN2ESR2 | |
| SCHEMBL136340 | 0.81 | — | — | |
| SCHEMBL294945 | 0.81 | — | — | |
| SCHEMBL19293693 | 0.78 | — | — | |
| SCHEMBL7366794 | 0.76 | NEK2 (0.35) | — | |
| SCHEMBL417593 | 0.76 | CYP11B2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023143393-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2023-08-03 | — | — | WO | disclosed |
| US-9453005-B2 | Inhibition of influenza M2 proton channel | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2015101928-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101928-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| US-9029544-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| EP-2536733-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2558462-B1 | Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8791288-B2 | Acid-labile ester monomer having spirocyclic structure, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791288-B2 | Acid-labile ester monomer having spirocyclic structure, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791288-B2 | Acid-labile ester monomer having spirocyclic structure, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| EP-1723116-B1 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1881827-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2008-01-30 | — | — | EP | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
| US-4418142-A | ALDEHYDE SCAVANGERS | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | SMN1; SMN2 884/4885ESR2 2574/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | SMN1; SMN2 1854/4885ESR2 520/4885 |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | SMN1; SMN2 1262/4885ESR2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.